Sugi Predict

Sugi Predict / Compounds / SCHEMBL2637544

SCHEMBL2637544

SCHEMBL2637544

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4(O)CCCC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1L1 Q9UHC9 5/20 0.66
▸ USP2 O75604 3/20 0.58
▸ LMNA P02545 3/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ TP53 P04637 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ CYP2D6 P10635 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ CDC25A P30304 4/20 0.55
▸ CDC25B P30305 1/20 0.55
▸ INPP5D Q92835 1/20 0.54
▸ FNTA P49354 2/20 0.54
▸ FNTB P49356 2/20 0.54
▸ SRD5A1 P18405 3/20 0.52
▸ SRD5A2 P31213 3/20 0.52
▸ ABCB1 P08183 1/20 0.50
▸ OSBP P22059 1/20 0.50
▸ RORC P51449 1/20 0.50
▸ OSBP2 Q969R2 1/20 0.50
▸ CYP46A1 Q9Y6A2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2637542 1.00 NPC1L1 (0.66) NPC1L1USP2LMNAMEN1TP53
SCHEMBL11793322 0.88 OSBP (0.60) NPC1L1OSBPRORCOSBP2
SCHEMBL11793318 0.88 OSBP (0.60) NPC1L1OSBPRORCOSBP2
SCHEMBL11784621 0.87 NPC1L1 (0.70) NPC1L1USP2LMNAMEN1TP53
SCHEMBL5059482 0.86 NPC1L1 (0.49) NPC1L1USP2LMNAMEN1TP53
SCHEMBL27573811 0.86 NPC1L1 (0.62) NPC1L1USP2LMNAMEN1TP53
SCHEMBL14490143 0.86 NPC1L1 (0.71) NPC1L1USP2LMNAMEN1TP53
SCHEMBL6900370 0.86 NPC1L1 (0.71) NPC1L1USP2LMNAMEN1TP53
SCHEMBL26642903 0.86 NPC1L1 (0.71) NPC1L1USP2LMNAMEN1TP53
SCHEMBL7117000 0.86 NPC1L1 (0.71) NPC1L1USP2LMNAMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10984899-B2 Platform and system for digital personalized medicine COGNOA, INC. (US) 2021-04-20 — — US claimed
US-20210035668-A1 PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE COGNOA, INC. 2021-02-04 — — US claimed
CN-110622179-A Platform and system for digital personalized medicine 科格诺亚公司 2019-12-27 — — CN claimed
US-20100116691-A1 BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF UNIVERSITY OF CONNECTICUT (US) 2010-05-13 — — US claimed
EP-0608600-A1 Cosmetic composition UNILEVER PLC (GB) 1994-08-03 — — EP claimed
US-3963765-A Preparation of derivatives of cholesterol MAZUR YEHUDA 1976-06-15 — — US claimed
CN-122056312-A Method for preparing walnut oil and non-preserved protein powder 江南大学 2026-05-19 — — CN disclosed
US-20250235544-A1 Tripartite Modulators of Endosomal G Protein-Coupled Receptors ENDOSOME THERAPEUTICS INC (US) 2025-07-24 — — US disclosed
US-12102644-B2 Compounds and methods of promoting myelination CASE WESTERN RESERVE UNIVERSITY (US) 2024-10-01 — — US disclosed
US-20230119819-A1 Tripartite Modulators of Endosomal G Protein-Coupled Receptors ENDOSOME THERAPEUTICS, INC. 2023-04-20 — — US disclosed
US-20230016698-A1 METHOD FOR DETERMINING GLUCOSE CONCENTRATION IN A SERUM SAMPLE KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2023-01-19 — — US disclosed
US-20230003682-A1 METHIONINE CONCENTRATION MEASUREMENT METHOD KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2023-01-05 — — US disclosed
CN-115531553-A Tri-part modulators of endosomal G protein-coupled receptors 武田药品工业株式会社 2022-12-30 — — CN disclosed
EP-0719133-A1 SKIN CARE METHOD AND COMPOSITION UNILEVER PLC (GB) 1996-07-03 — — EP disclosed
WO-1995007687-A1 SKIN CARE METHOD AND COMPOSITION UNILEVER PLC (GB) 1995-03-23 — — WO disclosed
WO-1995007688-A1 SKIN CARE METHOD AND COMPOSITION UNILEVER PLC (GB) 1995-03-23 — — WO disclosed
WO-1995007686-A1 SKIN CARE COMPOSITION COMPRISING THIOL PROTEASES FROM THE STRATUM CORNEUM UNILEVER PLC (GB) 1995-03-23 — — WO disclosed
EP-0608600-A1 Cosmetic composition UNILEVER PLC (GB) 1994-08-03 — — EP disclosed
EP-0587288-A1 Cosmetic composition containing a lipid and a hydroxy or ketacarboxylic acid UNILEVER PLC (GB) 1994-03-16 — — EP disclosed
US-4252719-A REMOVAL OF A TERTIARY HYDROGEN FROM A 5-A-STEROID BY CHLORINATING THE STEROID BEING FIRST ESTERIFIED BY AN IODOARYL-CONTAINING ESTERIFICATION AGENT RESEARCH CORPORATION (US) 1981-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119819-A1 Tripartite Modulators of Endosomal G Protein-Coupled Receptors NTSR1, NTSR2, MRGPRX2 NPC1L1 18/4885USP2 2510/4885LMNA 3107/4885
US-12102644-B2 Compounds and methods of promoting myelination MAG, GMFG, MYT1 NPC1L1 410/4885USP2 3419/4885LMNA 425/4885
US-20250235544-A1 Tripartite Modulators of Endosomal G Protein-Coupled Receptors NTSR1, NTSR2, MRGPRX2 NPC1L1 18/4885USP2 2510/4885LMNA 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback